ORIGINAL ARTICLE

Respiratory symptoms in people living with HIV and the effect of antiretroviral therapy: a systematic review and meta-analysis

James Brown,1,2 Anjana Roy,3 Ross Harris,3 Sarah Filson,1 Margaret Johnson,1 Ibrahim Abubakar,3,4 Marc Lipman1,2

ABSTRACT

Background Antiretroviral therapy (ART) has significantly altered the pattern of acute and chronic HIV-related disease. However, it is not clear what this means in terms of respiratory symptoms. We sought to investigate the association between HIV status and respiratory symptoms and how these have changed with the availability of ART.

Methods We searched Cochrane, Medline and Embase databases for studies published between 1946 and August 2015 comparing the prevalence of respiratory symptoms in populations with and without HIV infection. We undertook random effects meta-analysis of the main symptoms reported. We studied heterogeneity and completed sensitivity analyses and funnel plots.

Results From 5788 unique references identified, 24 papers provided relevant data: 18 documented the presence of cough and 11 examined the prevalence of breathlessness among other symptoms reported. Compared with the HIV negative, people living with HIV (PLWH) were more likely to have respiratory symptoms with pooled ORs for the prevalence of cough of 3.05 (95% CI 2.24 to 4.16) in resource-limited populations without access to ART; 2.18 (1.56 to 3.18) in resource-rich populations without access to ART and 1.11 (0.99 to 1.24) in resource-rich populations with access to ART. In resource-rich settings, although the availability of ART was associated with a reduction in the difference between HIV-positive and HIV-negative individuals, PLWH were more likely to report breathlessness, OR 1.39 (95% CI 1.11 to 1.73).

Conclusions Respiratory symptoms are more common in PLWH than controls. This association persists although at a reduced level in populations with access to ART.

INTRODUCTION

Antiretroviral therapy (ART) has altered the natural history of HIV-associated respiratory illness such that acute, life-threatening opportunistic respiratory infections (eg, Pneumocystis pneumonia) are much less common. This has reduced the incidence of AIDS-related respiratory pathology, for instance, there is clear evidence of a reduction in the incidence of TB after ART in all CD4 count strata.1 This means that HIV infection can be a manageable chronic illness, with people on ART having a life expectancy approaching that of the general population.2 However, HIV-positive people appear to continue to have an increased frequency of respiratory illness compared with the general population.3 This is important given that respiratory conditions are likely to become more common as populations age.

There is evidence from multiple sources of lung function impairment in people with long-standing HIV infection.4 5 Although most current evidence comes from cohorts in the USA or Europe and less is known about populations in other settings, higher rates of respiratory pathology despite antiretroviral treatment have been a consistent finding of studies in HIV-positive populations.6–8 There are likely to be several reasons for this, including higher rates of smoking and recreational drug use; lung injury occurring prior to antiretroviral treatment and possible consequences of the ongoing immune activation and disordered immune responses associated with HIV.9

Although objective impairment of lung function has received considerable recent attention, less attention has been paid to the symptoms that such individuals may experience. This is important, as lung function impairment can correlate poorly with symptoms and functional status.10 We sought, therefore, to provide a comprehensive analysis of existing data regarding respiratory symptoms in people living with HIV with the aim of understanding how this might have changed with ART, and where deficiencies in the current evidence base exist.

Key messages

What is the key question?

▸ Are respiratory symptoms more common in people living with HIV, and what effect has antiretroviral therapy had on this?

What is the bottom line?

▸ Our study suggests that respiratory impairment remains more common in HIV-positive adults despite the use of antiretroviral therapy.

Why read on?

▸ This is the first systematic evaluation of existing evidence regarding respiratory symptoms in people living with HIV, summarising the current evidence base and highlighting where deficiencies in this exist.
We provide a systematic review of the evidence regarding respiratory symptoms from population-based studies directly comparing HIV-positive and HIV-negative individuals with or without ART in both resource-limited and resource-rich settings, and a meta-analysis of the effect of HIV infection on the prevalence of these symptoms.

**METHODS**

**Search strategy**

Our aim was to evaluate evidence regarding the relative frequency of respiratory symptoms in HIV-positive and HIV-negative populations. We chose search terms that would capture any respiratory symptom (excluding those arising from pathology of the ear, or of obstructive sleep apnoea). We did not set rigid definitions, for instance, regarding the duration of symptoms required to distinguish chronic from acute cough, and instead used those provided by the investigators of the primary studies. This review was registered with the PROSPERO database and details of the protocol are available (PROSPERO 2015:CRD42015013762).

We completed a systematic literature search of publications in the MEDLINE, EMBASE, Cochrane and CINAHL databases between 1946 and August 2015, as well as search of abstracts from the Conference of Retroviruses and Opportunistic Infections and International AIDS Society and American Thoracic Society conferences since 1982 where available. Searches were limited to humans and there was no language limitation.

Search terms included ‘HIV’ OR ‘Human Immunodeficiency virus’ OR ‘AIDS’ AND ‘Signs and symptoms, respiratory’ (MeSH heading) OR ‘cough’ OR ‘breathless’ OR ‘dyspnea’ OR ‘haemoptysis’ OR ‘short of breath’ (see online supplementary appendix 1).

**Study selection**

Studies were included if they were published in peer-reviewed journals and included both HIV-positive and HIV-negative participants, measured respiratory symptoms in each group and provided quantitative data. All age groups were included in the review and there were no language restrictions.

Exclusion criteria were as follows: studies reporting symptoms of obstructive sleep apnoea (such as hypersonomnolence); studies reporting symptoms arising from the ear (such as ear pain, discharge or hearing change); studies that did not include HIV-negative individuals; and studies reporting data with the intention of describing a specific condition (eg, TB, bacterial or *Pneumocystis jirovecii* pneumonia) rather than the occurrence of symptoms within the general or HIV-positive population. This included studies evaluating hospital in-patients alone, as these would not be representative of the population as a whole. We did not exclude population-based studies if, by chance, they contained people with prevalent respiratory conditions as part of the general (HIV-positive or HIV-negative) population under test.

**Data extraction**

All abstracts were independently reviewed by two members of the review team. Shortlisted full-text articles were then jointly reviewed by two reviewers based on the inclusion/exclusion criteria. Where necessary, discrepancies were resolved by discussion with a senior member of the team.

Data were extracted on the following study characteristics: study design, date of study, age and gender of participants, prevalence of tobacco smoking, risk of acquisition of HIV, geographical location(s) of study, number of HIV-positive and HIV-negative participants, frequency of respiratory symptoms, description of respiratory symptoms/tool used to evaluate, availability of antiretroviral treatment, treatment provided for the respiratory illness, level of immunocompromise in the HIV-positive group (eg, median blood CD4 count).

The risk of bias in observational studies was assessed using a modified Newcastle Ottawa Scale (see online supplementary appendix 2); the version used by Herzog *et al* for the evaluation of cross-sectional studies was modified with criteria selected appropriate to this field. This scale awarded up to eight points to each study: three points for the adequate selection of participants, three points for comparability of the HIV-positive and HIV-negative participants included in the study and two points for the assessment of symptoms and reporting of statistical tests. In this scale, stars are awarded for higher scores in each criterion, giving a total score out of a possible 8 stars. We defined studies of high quality as those that scored 6–8 stars, moderate quality 5 or 6 stars and low quality those with 0–3 stars.

**Statistical analysis**

The relative prevalence of respiratory symptoms in HIV-positive and HIV-negative groups was compared using ORs: although different definitions of symptoms were used by the investigators of the primary studies (meaning that the absolute prevalence of particular symptoms varied considerably), the relative frequency of symptoms in HIV-positive and HIV-negative participants could be compared by means of ORs, thus allowing estimation of the effect of HIV infection on the likelihood of having these symptoms.

Studies of adults were stratified by location of study into resource-limited and resource-rich settings (which also equated with high and low TB prevalence and high and low HIV prevalence settings) and availability of ART (as reported by the authors). This stratification was undertaken because the aetiology and determinants of respiratory illness were likely to differ between these settings. Studies evaluating children were not included in the quantitative synthesis as these represent a unique population and these studies were highly heterogeneous in methodology and outcome. Meta-analysis was conducted using RevMan V5.3 (The Cochrane Collaboration, 2014).

Pooled ORs for the presence of specific respiratory symptoms were calculated within each stratum wherever more than one study provided data. The DerSimonian and Laird random effects model was used to account for between-study heterogeneity. Statistical heterogeneity was assessed using the Cochran *χ*² test and the *I*² statistic was used to summarise the degree of variation; causes of heterogeneity were further explored by meta-regression. A priori factors chosen for meta-regression were the proportion of HIV-positive individuals with undetectable viral load and the log OR of smoking in HIV-positive versus HIV-negative groups. The possibility that small studies have more extreme results (due to reporting bias) was assessed by the visual inspection of funnel plots.

**RESULTS**

A total of 5788 publications were identified by our database search after removal of duplicate publications. Of these, 5596 were excluded after review of the article title and abstract. One hundred and ninety-two potentially relevant articles were reviewed in full text, of which 154 were excluded; reasons for exclusion are given in figure 1. Twenty-four publications were included in the final list for review (table 1). Using a modified Newcastle Ottawa Scale, 6 studies were rated as low quality, 14 as moderate quality and 4 as high quality (see online supplementary appendix 3).
Characteristics of included studies and data presented

All studies included were observational studies, although two papers investigated cohorts recruited as part of randomised trials.20-24 With the exception of five studies following birth cohorts over time, all studies were either cross-sectional in nature or reported data arising from prospective cohorts at a single time point.

The earliest study recruited patients from 1985,15 with the most recent provided data collected in 2012.32 Eight articles reported research conducted in the USA (detailing 9 separate studies), with 12 studies conducted in Africa, 2 in Asia and 2 in Europe (both from Italy). Nineteen studies included adult patients and five evaluated infants only.

The presence of cough and breathlessness were the most common symptoms evaluated: data on cough were presented by 17 of 19 studies in adults. Definitions of cough varied, with the most common being the presence of cough for >2 weeks (tables 2–6). Frequency of breathlessness was reported by 11 studies. Usually this was defined only as the presence of ‘dyspnoea’, ‘breathlessness’ or ‘shortness of breath’, though four studies (all evaluating adults with access to ART) used the Medical Research Council (MRC) dyspnoea score as a standardised measure.35

Studies that examined respiratory symptoms in HIV-positive adults without access to ART

Twelve studies provided data regarding respiratory symptoms in HIV-positive adults without access to ART (tables 2 and 3). All of these demonstrated a greater proportion of HIV-positive participants with respiratory symptoms. Five studies reported prevalence of breathlessness (two from the USA, others from Nigeria, Zimbabwe and India).

Three studies provided data on respiratory symptoms in HIV-positive populations in the first decade of the HIV epidemic in the USA. The Multicenter AIDS Cohort Study collected data from a cohort of MSM at four sites from 1985 onwards; el Sadr et al studied a cohort of injection drug users in New York and Diaz et al evaluated a cohort of predominantly white men in Ohio. Data on respiratory symptoms in these populations are presented in table 3.

Nine studies reported the prevalence of respiratory symptoms in HIV-positive and HIV-negative individuals without access to ART in resource-limited settings, and seven of these were in sub-Saharan African populations. The earliest of these used data from Rwanda collected in 1988, and the most recent was from Antwal et al in 2014. Only two studies evaluated populations outside of the USA and Africa (Kheaw-on et al in Cambodia and Antwal et al in India).

Studies that examined symptoms in HIV-positive children

Five studies reported the prevalence of respiratory symptoms in HIV-positive and HIV-negative children (table 4). All of these evaluated cohorts of vertically infected infants followed up from birth, and no studies assessed older children. The earliest was conducted in Rwanda from 1988 with subsequent work in...
<table>
<thead>
<tr>
<th>First author and reference</th>
<th>Year of publication</th>
<th>Design of study</th>
<th>Risk for HIV</th>
<th>Study location</th>
<th>Total number of participants</th>
<th>% HIV+</th>
<th>Respiratory data collected</th>
<th>Quality rating*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lepage13</td>
<td>1991</td>
<td>Cross-sectional</td>
<td>General population</td>
<td>Rwanda</td>
<td>431</td>
<td>50</td>
<td>Persistent cough &gt;1 month</td>
<td>Moderate</td>
</tr>
<tr>
<td>el Sadr14</td>
<td>1992</td>
<td>Prospective cohort</td>
<td>IDU</td>
<td>USA</td>
<td>223</td>
<td>56</td>
<td>Standardised symptom checklist (SCS22)</td>
<td>Moderate</td>
</tr>
<tr>
<td>Hoover15</td>
<td>1993</td>
<td>Prospective cohort</td>
<td>MSM</td>
<td>USA</td>
<td>2854</td>
<td>29</td>
<td>New or unusual cough</td>
<td>Moderate</td>
</tr>
<tr>
<td>Hoover—visit 7</td>
<td>1993</td>
<td>Cross-sectional</td>
<td>MSM</td>
<td>Guinea-Bissau</td>
<td>2215</td>
<td>29</td>
<td>Cough &gt;1 month</td>
<td>Moderate</td>
</tr>
<tr>
<td>Spira17</td>
<td>1999</td>
<td>Prospective (birth) cohort</td>
<td>Vertical transmission</td>
<td>Rwanda</td>
<td>401</td>
<td>13</td>
<td>Persistent cough</td>
<td>Moderate</td>
</tr>
<tr>
<td>Olayinka18</td>
<td>1999</td>
<td>Prospective (birth) cohort</td>
<td>Vertical transmission</td>
<td>Zimbabwe</td>
<td>272</td>
<td>16</td>
<td>Cough since last review</td>
<td>Low</td>
</tr>
<tr>
<td>Nilses19</td>
<td>2000</td>
<td>Cross-sectional</td>
<td>General population</td>
<td>Zimbabwe</td>
<td>1213</td>
<td>22</td>
<td>Dyspnoea, cough</td>
<td>Moderate</td>
</tr>
<tr>
<td>Taha20</td>
<td>2000</td>
<td>Prospective (birth) cohort</td>
<td>Vertical transmission</td>
<td>Malawi</td>
<td>808</td>
<td>24</td>
<td>History of wheezy illness collected at clinic appointments</td>
<td>Moderate</td>
</tr>
<tr>
<td>Diaz21</td>
<td>2003</td>
<td>Cross-sectional</td>
<td>General population</td>
<td>USA</td>
<td>379</td>
<td>86</td>
<td>Rejection of intercostal muscles, wheezing, cough, active nasal flaring or rales at follow-up visits</td>
<td>Moderate</td>
</tr>
<tr>
<td>Galli22</td>
<td>2003</td>
<td>Cross-sectional</td>
<td>Vertical transmission</td>
<td>Italy</td>
<td>2060</td>
<td>4</td>
<td>New or worsening cough (&gt;2 weeks or &gt;3 weeks)</td>
<td>Low</td>
</tr>
<tr>
<td>Lewis23</td>
<td>2009</td>
<td>Cross-sectional</td>
<td>Vertical transmission</td>
<td>South Africa</td>
<td>1955</td>
<td>29</td>
<td>Haemoptysis</td>
<td>Moderate</td>
</tr>
<tr>
<td>Read24</td>
<td>2009</td>
<td>Prospective (birth) cohort</td>
<td>Vertical transmission</td>
<td>Malawi, Tanzania, Zambia</td>
<td>1317</td>
<td>6</td>
<td>Chronic cough (&gt;14 days)</td>
<td>Moderate</td>
</tr>
<tr>
<td>Kheaw-On26</td>
<td>2009</td>
<td>Cross-sectional</td>
<td>General population</td>
<td>Thailand</td>
<td>210</td>
<td>50</td>
<td>History of chronic cough</td>
<td>Low</td>
</tr>
<tr>
<td>Corbett27</td>
<td>2010</td>
<td>Cross-sectional</td>
<td>General population</td>
<td>Zimbabwe</td>
<td>8979</td>
<td>21</td>
<td>Cough &lt;2 weeks. Cough &gt;3 weeks, haemoptysis</td>
<td>Low</td>
</tr>
<tr>
<td>Drummond27</td>
<td>2010</td>
<td>Prospective cohort</td>
<td>IDU</td>
<td>USA</td>
<td>974</td>
<td>30</td>
<td>Modified ATS-DLD-78 MRC dyspnoea scale</td>
<td>High</td>
</tr>
<tr>
<td>Onyedum28</td>
<td>2010</td>
<td>Cross-sectional</td>
<td>General population</td>
<td>Nigeria</td>
<td>200</td>
<td>50</td>
<td>Cough, cough with sputum, breathlessness, wheezing</td>
<td>Low</td>
</tr>
<tr>
<td>Gounder29</td>
<td>2011</td>
<td>Cross-sectional</td>
<td>General population</td>
<td>South Africa</td>
<td>3937</td>
<td>37</td>
<td>Cough &gt;2 weeks. Sputum production</td>
<td>Moderate</td>
</tr>
<tr>
<td>Crothers8, Lung HIV Study</td>
<td>2013</td>
<td>Prospective cohort</td>
<td>Mixed</td>
<td>USA</td>
<td>589</td>
<td>51</td>
<td>Usual cough/phlegm, wheezing (ATS-DLD-78)</td>
<td>High</td>
</tr>
<tr>
<td>Fitzpatrick28, WHIS</td>
<td>2013</td>
<td>Prospective cohort</td>
<td>Mixed</td>
<td>USA</td>
<td>99</td>
<td>64</td>
<td>ATS-DLD questionnaire</td>
<td>High</td>
</tr>
<tr>
<td>Madeddu30</td>
<td>2013</td>
<td>Cross-sectional</td>
<td>MSM</td>
<td>Italy</td>
<td>176</td>
<td>63</td>
<td>Symptom questionnaire MRC dyspnoea scale</td>
<td>Moderate</td>
</tr>
<tr>
<td>Antwal31</td>
<td>2014</td>
<td>Cross-sectional</td>
<td>Not detailed</td>
<td>India</td>
<td>1546</td>
<td>35</td>
<td>Breathlessness, cough with sputum</td>
<td>Moderate</td>
</tr>
</tbody>
</table>
**Table 1** Continued

<table>
<thead>
<tr>
<th>First author and reference</th>
<th>Year of publication</th>
<th>Design of study</th>
<th>Risk for HIV</th>
<th>Study location</th>
<th>Total number of participants</th>
<th>% HIV+</th>
<th>Respiratory data collected</th>
<th>Study location</th>
<th>Quality rating*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campo32</td>
<td>2014</td>
<td>Prospective cohort</td>
<td>Mixed</td>
<td>USA</td>
<td>340</td>
<td>53</td>
<td>Chronic cough (for most days for 3 months or more per year for &gt;1 year), chronic phlegm, wheeze, MRC dyspnoea scale</td>
<td>USA</td>
<td>Moderate</td>
</tr>
<tr>
<td>Gingo33 (MACS)</td>
<td>2014</td>
<td>Prospective cohort</td>
<td>MSM</td>
<td>USA</td>
<td>1896</td>
<td>48</td>
<td>ATS-DLD-78 questionnaire</td>
<td>USA</td>
<td>High</td>
</tr>
<tr>
<td>Gingo (WIHS)</td>
<td>2014</td>
<td>Prospective cohort</td>
<td>Mixed</td>
<td>USA</td>
<td>1976</td>
<td>71</td>
<td>ATS-DLD-78 questionnaire</td>
<td>USA</td>
<td>Low</td>
</tr>
<tr>
<td>Telisinghe34</td>
<td>2014</td>
<td>Cross-sectional General population</td>
<td>South Africa</td>
<td>846</td>
<td>25</td>
<td>Chronic cough (&gt;14 days)</td>
<td>South Africa</td>
<td>Low</td>
<td></td>
</tr>
</tbody>
</table>

*Modified Newcastle Ottawa Scale.
†Data arising from prospective cohort studies; however, data used in quantitative analyses for this review from single time point.
IDU, injection drug user; MACS, Multi-Centre AIDS Cohort Study; MSM, men who have sex with men; VACS, Veterans Aging Cohort Study; WIHS, Women’s Interagency HIV Study.

**Table 2** Respiratory symptoms in resource-limited settings without access to ART

<table>
<thead>
<tr>
<th>First author</th>
<th>Year of publication</th>
<th>Study location</th>
<th>Total N</th>
<th>% HIV+</th>
<th>HIV+ on ART (%)</th>
<th>Mean/median blood CD4*</th>
<th>% HIV+ Smokers</th>
<th>% HIV− smokers</th>
<th>Definition of cough used</th>
<th>% HIV+ with cough</th>
<th>% HIV− with cough</th>
<th>Definition of breathlessness</th>
<th>% HIV+ with breathlessness</th>
<th>% HIV− with breathlessness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lepage13</td>
<td>1991</td>
<td>Rwanda</td>
<td>431</td>
<td>50</td>
<td>0</td>
<td>24% CD4:CD8 &lt;0.5</td>
<td>NR</td>
<td>NR</td>
<td>Persistent cough &gt;1 month</td>
<td>14</td>
<td>7</td>
<td>Dyspnoea</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Norrgren16</td>
<td>1998</td>
<td>Guinea-Bissau</td>
<td>2215</td>
<td>9</td>
<td>0</td>
<td>715 (men) 430 (women)</td>
<td>NR</td>
<td>NR</td>
<td>Cough &gt;1 month</td>
<td>3</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nilse19</td>
<td>2000</td>
<td>Zimbabwe</td>
<td>1213</td>
<td>21</td>
<td>0</td>
<td>NS</td>
<td>NR</td>
<td>NR</td>
<td>History of chronic cough</td>
<td>57</td>
<td>31</td>
<td>New or worsening cough, any duration &gt;2 weeks &gt;3 weeks</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Kheaw-On25</td>
<td>2009</td>
<td>Thailand</td>
<td>210</td>
<td>50</td>
<td>NR</td>
<td>261</td>
<td>36</td>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td>Breathlessness</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Lewis23</td>
<td>2009</td>
<td>South Africa</td>
<td>1955</td>
<td>29</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corbett26</td>
<td>2010</td>
<td>Zimbabwe</td>
<td>8979</td>
<td>21</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Cough for 2 weeks or more</td>
<td>8</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Onyedum38</td>
<td>2010</td>
<td>Nigeria</td>
<td>200</td>
<td>50</td>
<td>0</td>
<td>71% CD4 &lt;200</td>
<td>0</td>
<td>0</td>
<td>Cough</td>
<td>48</td>
<td>8</td>
<td>Breathlessness</td>
<td>32</td>
<td>0</td>
</tr>
<tr>
<td>Gounder29</td>
<td>2011</td>
<td>South Africa</td>
<td>3937</td>
<td>37</td>
<td>NR</td>
<td>333</td>
<td>NR</td>
<td>NR</td>
<td>Cough for 2 weeks or longer</td>
<td>7</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antwal31</td>
<td>2014</td>
<td>India</td>
<td>1546</td>
<td>35</td>
<td>0</td>
<td>241</td>
<td>NR</td>
<td>NR</td>
<td>Cough with sputum</td>
<td>10</td>
<td>2</td>
<td>Breathlessness</td>
<td>4</td>
<td>1</td>
</tr>
</tbody>
</table>

*Cells per microlitre unless otherwise stated. ART, antiretroviral therapy; NR, not reported.
Table 3  Studies in resource-rich settings without access to ART

<table>
<thead>
<tr>
<th>First author</th>
<th>Year</th>
<th>Study location</th>
<th>Total number of participants</th>
<th>% HIV+</th>
<th>Risk for HIV</th>
<th>Mean/median blood CD4*</th>
<th>% HIV+ smokers</th>
<th>% HIV– smokers</th>
<th>Definition of cough used</th>
<th>% HIV+ with cough</th>
<th>% HIV– with cough</th>
<th>Definition of breathlessness</th>
<th>% HIV+ with breathlessness</th>
<th>% HIV– with breathlessness</th>
</tr>
</thead>
<tbody>
<tr>
<td>el Sadr14</td>
<td>1992</td>
<td>USA</td>
<td>223</td>
<td>56</td>
<td>IDU</td>
<td>0</td>
<td>200–500</td>
<td>NR</td>
<td>Persistent cough</td>
<td>17</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hoover—visit 7</td>
<td>1993</td>
<td>USA</td>
<td>2854</td>
<td>33</td>
<td>MSM</td>
<td>0</td>
<td>619</td>
<td>NR</td>
<td>New or unusual cough lasting &gt;2 weeks</td>
<td>5</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hoover—visit 7</td>
<td>1993</td>
<td>USA</td>
<td>2627</td>
<td>29</td>
<td>MSM</td>
<td>0</td>
<td>552</td>
<td>NR</td>
<td>Do you usually have a cough?</td>
<td>40</td>
<td>25</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diaz21</td>
<td>2003</td>
<td>USA</td>
<td>379</td>
<td>86</td>
<td>MSM</td>
<td>0</td>
<td>370</td>
<td>54</td>
<td>Do you usually cough like this on most days For ≥3 consecutive months of the year?</td>
<td>24</td>
<td>12</td>
<td></td>
<td>20</td>
<td>0</td>
</tr>
</tbody>
</table>

*Cells per microlitre.
ART, antiretroviral therapy; IDU, injection drug user; MSM, men who have sex with men.

Table 4  Studies evaluating children (cohorts followed up from birth)

<table>
<thead>
<tr>
<th>First author</th>
<th>Year of publication</th>
<th>Study location</th>
<th>Total number of participants</th>
<th>% HIV+</th>
<th>% HIV+ on ART</th>
<th>Duration of follow-up (from birth)</th>
<th>Respiratory data collected</th>
<th>Notes/comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spira17</td>
<td>1999</td>
<td>Rwanda</td>
<td>401</td>
<td>13</td>
<td>0</td>
<td>Median 27 months (HIV-positive group), 51 months (HIV-negative group)</td>
<td>Chronic cough (&gt;14 days)</td>
<td>Measured cumulative incidence of developing a cough lasting &gt;14 days</td>
</tr>
<tr>
<td>Olayinka18</td>
<td>1999</td>
<td>Zimbabwe</td>
<td>272</td>
<td>16</td>
<td>0</td>
<td>24 months</td>
<td>Persistent cough</td>
<td>2 HIV-negative groups—exposed uninfected infants and unexposed. Rate of cough the same in each.</td>
</tr>
<tr>
<td>Taha20</td>
<td>2000</td>
<td>Malawi</td>
<td>689</td>
<td>19</td>
<td>0</td>
<td>Median 18 months</td>
<td>Cough since last review</td>
<td></td>
</tr>
<tr>
<td>Galli22</td>
<td>2003</td>
<td>Italy</td>
<td>280</td>
<td>75</td>
<td>25</td>
<td>24 months</td>
<td>History of wheezy illness collected at clinic appointments</td>
<td>Presents proportion of infants with wheezy illness in first 2 years of life</td>
</tr>
<tr>
<td>Read24</td>
<td>2009</td>
<td>Malawi, Tanzania, Zambia</td>
<td>1317</td>
<td>84</td>
<td>0</td>
<td>12 months</td>
<td>Retraction of intercostal muscles, wheezes, cough, active nasal flaring or rales at follow-up visits</td>
<td>HPTN 024 study cohort, studied 2001–2004</td>
</tr>
</tbody>
</table>

ART, antiretroviral therapy; HPTN, The HIV Prevention Trials Network.
### Table 5  Studies evaluating populations in resource-rich settings with access to ART

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Study location</th>
<th>Total number of participants</th>
<th>% HIV+</th>
<th>HIV+ on ART (%)</th>
<th>% undetectable HIV plasma load</th>
<th>Mean/median blood CD4</th>
<th>% HIV+ smokers</th>
<th>% HIV--smokers</th>
<th>Definition of cough</th>
<th>% HIV+ with cough</th>
<th>% HIV--with cough</th>
<th>Definition of breathlessness</th>
<th>% HIV+ with breathlessness</th>
<th>% HIV-- with breathlessness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drummond(^7) ALIVE cohort</td>
<td>2010</td>
<td>USA</td>
<td>974</td>
<td>30</td>
<td>54</td>
<td>16.5</td>
<td>320</td>
<td>83</td>
<td>86</td>
<td>Cough present</td>
<td>3</td>
<td>29</td>
<td>MRC dyspnoea score ≥2</td>
<td>35</td>
<td>28</td>
</tr>
<tr>
<td>Crothers(^8) Lung HIV study</td>
<td>2013</td>
<td>USA</td>
<td>589</td>
<td>51</td>
<td>89</td>
<td>84</td>
<td>493</td>
<td>47</td>
<td>35</td>
<td>Morning cough ≥4 days per week</td>
<td>19</td>
<td>19</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fitzpatrick(^7) WIHS</td>
<td>2013</td>
<td>USA</td>
<td>99</td>
<td>64</td>
<td>81</td>
<td>NS</td>
<td>426</td>
<td>46</td>
<td>50</td>
<td>Morning cough ≥3 months</td>
<td>15</td>
<td>15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macheddu(^10)</td>
<td>2013</td>
<td>Italy</td>
<td>176</td>
<td>63</td>
<td>78</td>
<td>71</td>
<td>541</td>
<td>57</td>
<td>58</td>
<td>Unusual cough</td>
<td>28</td>
<td>20</td>
<td>MRC dyspnoea score ≥2</td>
<td>15</td>
<td>11</td>
</tr>
<tr>
<td>Campo(^32) EXHALE substudy, VACS cohort</td>
<td>2014</td>
<td>USA</td>
<td>340</td>
<td>53</td>
<td>89</td>
<td>NS</td>
<td>431</td>
<td>64</td>
<td>58</td>
<td>Cough</td>
<td>32</td>
<td>14</td>
<td>MRC dyspnoea score ≥2</td>
<td>31</td>
<td>15</td>
</tr>
<tr>
<td>Gingo(^33) MACS</td>
<td>2014</td>
<td>USA</td>
<td>1896</td>
<td>48</td>
<td>77</td>
<td>70</td>
<td>572</td>
<td>31</td>
<td>23</td>
<td>Chronic cough</td>
<td>25</td>
<td>16</td>
<td>MRC dyspnoea score ≥2</td>
<td>25</td>
<td>16</td>
</tr>
<tr>
<td>Gingo(^33) WIHS</td>
<td>2014</td>
<td>USA</td>
<td>1976</td>
<td>71</td>
<td>76</td>
<td>56</td>
<td>502</td>
<td>39</td>
<td>52</td>
<td>Cough</td>
<td>54</td>
<td>58</td>
<td>Dyspnoea</td>
<td>36</td>
<td>37</td>
</tr>
</tbody>
</table>

ART, antiretroviral therapy; MACS, Multi-Centre AIDS Cohort Study; VACS, Veterans Aging Cohort Study; WIHS, Women’s Interagency HIV Study.
Malawi and Zimbabwe. None of these study populations had access to ART.

One study evaluated symptoms in HIV-positive infants born in Chieti, Italy; this suggested a lower frequency of ‘wheezy respiratory illness’ in HIV-positive infants despite more maternal smoking, premature delivery, low birth rate and formula feeding. However, the design of the study (based on routine clinic records) did not allow appraisal of the possibility of differences in health-seeking behaviour or reporting of acute respiratory illness, which could bias the comparison of respiratory symptoms between the different groups.

Studies that examined respiratory symptoms in HIV-positive adults with access to ART
Six studies (using data from seven cohorts) reported on adults with access to ART. All were from resource-rich settings other than one from South Africa. Data on respiratory symptoms are presented in tables 5 and 6.

All contained a high proportion of current smokers in both the HIV-positive and HIV-negative groups and, where reported, often had high rates of former or ongoing recreational drug use.

The first systematic comparison of respiratory symptoms in a HIV-positive population with access to ART with HIV-negative comparators is provided by the AIDS Linked to the IntraVenous Experience (ALIVE) cohort of former and current injection drug users in Baltimore, Maryland, USA. This found no difference in frequency of current cough, although a history of ‘wheezeing’ was reported by 50% of HIV-positive and 37% of HIV-negative participants.

Several cohort studies have addressed respiratory symptoms in HIV-positive individuals with access to ART in the USA: the Women’s Intercagency HIV Study (WIHS); Multicentre AIDS Cohort Study and the EXHALE substudy of the Veterans Aging Cohort Study. Tobacco use was high in these cohorts, and smoking was more frequent in the HIV-positive than HIV-negative groups (reported in 39%–64% and 23%–58%, respectively). The prevalence of respiratory symptoms was high in these populations, for instance Fitzpatrick et al described breathlessness in 35% of HIV-positive and 31% of HIV-negative participants in the WIHS study and Campo et al reported cough in 25% of HIV-positive and 16% in HIV-negative participants in the EXHALE VACS substudy.

There is little information comparing respiratory symptoms in HIV-negative and HIV-positive individuals with access to ART outside of North America. The only study providing data from Europe documented the presence of any respiratory symptom in 47% HIV-positive participants and 23% of HIV-negative participants, with 32% vs 14% reporting cough (p=0.006) and 31% vs 15% breathlessness (p=0.02). Tellinghine et al evaluated a prison population in South Africa (with a 25% HIV prevalence) in which cough lasting 2 weeks or more was present in 13% of HIV-positive and 8% of HIV-negative individuals. 36% of the HIV-positive participants reported the use of ART.

The prevalence of tobacco smoking was only consistently reported in studies undertaken in resource-rich settings with access to ART. In all of these studies, a large proportion of both HIV-positive and HIV-negative participants were current smokers (see table 5), and this was similar across these groups.

Quantitative data synthesis
Data were available on 12,075 HIV-positive individuals compared with 24,450 individuals without HIV infection. The symptoms for which sufficient data were available to allow quantitative synthesis were cough and breathlessness. Figures 2 and 3 demonstrate the ORs for the presence of cough and breathlessness in those with and without access to ART and in resource-rich and resource-limited settings.

Meta-analysis suggests that the availability of ART is associated with a reduction in the difference in prevalence of respiratory symptoms between HIV-positive and HIV-negative individuals, yet these remain more common in people living with HIV. There is little evidence regarding respiratory symptoms in HIV-positive populations in resource-limited settings. The pooled OR for the presence of cough in such populations without access to ART was 3.05 (95% CI 2.24 to 4.16, I²=68%); in resource-rich populations without access to ART, it was 2.18 (1.55 to 3.04 I²=0%), and in those from resource-rich settings with access to ART, the OR for the presence of cough was 1.26 (0.97 to 1.63) —although there was a substantial degree of heterogeneity in this analysis (I²=74%). Only one study reported frequency of cough in a high-prevalence setting with access to ART.

Breathlessness was also assessed, although fewer studies reported this. In resource-limited settings without access to ART, the OR for the prevalence of breathlessness was 7.5 (0.92 to 61.31, I²=83%). Only two studies were available from resource-rich settings without access to ART, and meta-analysis of these data provides an OR of 2.60 (0.25 to 26.93, I²=93%). In resource-rich settings with access to ART, there was good evidence for a higher rate of breathlessness in HIV-positive individuals with an OR of 1.39 (1.11 to 1.73, I²=52%).

Funnel plots were inspected to evaluate the possibility of reporting or publication bias where sufficient studies were available within each stratum of ART availability and location to make this useful. For the most part these did not suggest the presence of significant reporting bias (eg, see online supplementary figure S1) although this was possible for the apparent association between breathlessness in HIV-positive populations with access to ART (see online supplementary figure S2). As there were fewer than 10 studies within each stratum, quantitative tests of reporting bias were not used, in accordance with the Cochrane Handbook guidance.

Sensitivity analyses
Two studies (Onyedum 2010 and Antwal 2014) included in the analysis of respiratory symptoms in populations without access to ART were judged to be at high risk of bias due to the inclusion of significant numbers of participants presenting for care with acute respiratory illnesses due to their methodology (which involved recruitment within acute care services). Exclusion of these studies reduced somewhat the effect size for the prevalence of cough to an OR of 2.84 (2.45 to 3.30) as well as the heterogeneity in this analysis (I²=55%).

Four studies (all in populations with access to ART) used the MRC dyspnoea scale to measure breathlessness (see table 5). A meta-analysis including only studies using the MRC dyspnoea scale (with breathlessness defined as a score of ≥2) did not significantly change the effect size (compared with the analysis of all studies reporting the prevalence of breathlessness in populations with access to ART) but reduced heterogeneity significantly (OR for having MRC dyspnoea ≥2=1.50, 95% CI 1.21 to 1.85, I²=0%, online supplementary figure S3).

The true effect of HIV status on respiratory symptoms may be exaggerated by the higher proportion of HIV-positive subjects who were current smokers in several of the included studies, as few studies provided data adjusted for smoking status. Meta-regression confirmed an association between higher rates of respiratory symptoms in studies with a greater imbalance of smokers versus non-smokers in the HIV-positive
compared with HIV-negative group (data not shown). However, this had little impact on the estimated effect of HIV infection on the frequency of cough or breathlessness.

**DISCUSSION**

This systematic review and meta-analysis demonstrates that despite the availability of ART, HIV-positive populations continue to experience more respiratory symptoms than comparable HIV-negative groups, at least in resource-rich settings for which there are sufficient data to draw conclusions. It also highlights several research needs: in particular the lack of rigorous data concerning respiratory symptoms in HIV-positive populations in low-income and middle-income settings where the majority of the world’s HIV-positive individuals live.

The successful provision of ART means that HIV-positive populations can expect considerable improvements in life expectancy; however, ageing HIV-positive populations have more comorbidities and respiratory illness is likely to become increasingly important over time. An improved understanding of the health needs of ageing HIV-positive populations is required,

### Table 6  
Studies evaluating populations in resource-limited settings with access to ART

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Study location</th>
<th>Total number of participants</th>
<th>% HIV+</th>
<th>% on ART (%)</th>
<th>% Undetectable HIV plasma load</th>
<th>Mean/median blood CD4</th>
<th>% HIV+ smokers</th>
<th>% HIV− smokers</th>
<th>Definition of cough</th>
<th>% HIV+ with cough</th>
<th>% HIV− with cough</th>
</tr>
</thead>
<tbody>
<tr>
<td>Telisinghe et al.</td>
<td>2014</td>
<td>South Africa</td>
<td>846</td>
<td>25</td>
<td>41</td>
<td>NS</td>
<td>NS</td>
<td>59</td>
<td>59</td>
<td>Cough &gt;2 weeks</td>
<td>13</td>
<td>8</td>
</tr>
</tbody>
</table>

**NOTE:** ART, antiretroviral therapy.

**Figure 2**  
Forest plot of ORs for presence of cough, stratified by availability of ART and location. ART, antiretroviral therapy; MACS, Multicentre AIDS Cohort Study; WIHS, Women’s Interagency HIV Study.
as even in resource-rich settings, the impact of respiratory illness on individuals (measured by instruments designed to evaluate health-related quality of life) or at a societal health-economic level is evaluated infrequently in HIV-positive populations.

In resource-rich settings, HIV-positive populations often have greater cigarette and recreational drug use than the general population.\textsuperscript{41} 42 Interventions to reduce this are therefore important, given that there is accumulating evidence of increased rates of both cardiovascular and respiratory illness. In some high HIV prevalence settings, tobacco smoking is rising fast,\textsuperscript{43} and attention should be given to the possibility that HIV-positive individuals may be particularly susceptible to the harmful effects of tobacco smoking.\textsuperscript{44}

Strengths of this analysis include a comprehensive search strategy and robust methods for study selection. Limitations include the lack of standardised assessments of respiratory symptoms in the primary studies, and incomplete reporting of important confounding factors (eg, smoking and recreational drug use), which may influence the effect sizes found. The incomplete reporting of exposures such as tobacco smoking and drug use in the original papers means that the extent to which the association identified between HIV status and respiratory symptoms is a direct result of the HIV virus is uncertain as we were not able to adjust for differing exposures to these possible confounding factors between HIV-positive and HIV-negative individuals. Another important limitation is that the data included in the quantitative meta-analyses were cross-sectional in nature and we cannot therefore infer causation from such studies. Bias or confounding in the primary studies may be one cause of the association between HIV status and respiratory symptoms found, and the strength of conclusions that can be drawn is therefore limited by the paucity of evidence in many areas.

One difficulty when evaluating respiratory symptoms is the challenge of standardising assessments: The wide range in the reported frequency of respiratory symptoms arises in part from the diversity of methods used to evaluate them: the definitions used for symptoms such as cough or breathlessness were often not stated, and a minority of studies used validated tools such as the St George’s Respiratory Questionnaire,\textsuperscript{45} American Thoracic Society Division of Lung Disease questionnaire\textsuperscript{46} or the MRC dyspnoea scale (see tables 2–6 for details of data collected in each study).\textsuperscript{35} Furthermore, results were presented as the proportion/number with respiratory symptoms, with no study reporting estimates adjusted for potential confounders.

It is important to note that although populations may have access to ART, most studies include a significant proportion of participants who were either not using ART, or who do not have an undetectable viral load. We cannot therefore estimate the effect of HIV infection at an individual level in those with a favourable virological and immunological response to ART. Furthermore, most of the data regarding populations with access to ART derive from the USA and there is limited information from other settings. Exposures of importance that could lead to respiratory disease may differ in other locations, and the findings of the studies included in this review may not be generalisable—for instance, to HIV-positive African populations using ART.

Our analysis suggests that despite the availability of ART, HIV-positive individuals are more likely to experience respiratory symptoms than those without HIV. Part of the reason for this higher burden of symptoms is likely to be the greater prevalence of tobacco smoking and recreational drug use in many

![Figure 3 OR for the presence of breathlessness, random effects meta-analysis stratified by location and availability of antiretroviral therapy.](https://doi.org/10.1136/thoraxjnl-2016-208657)
HIV-positive populations, particularly in resource-rich countries. However, direct HIV-related mechanisms may also play a role: although ART treatment achieves virological suppression for the majority of people treated, derangements of immune function persist despite treatment, which include evidence of ongoing immunological activation, which may promote the development of comorbid disease.\(^4\) There is growing evidence that this is clinically important for the development of cardiovascular disease\(^4\) and may also be relevant for respiratory pathology— for instance, Attia et al demonstrated an association between soluble CD14 (a marker of immune activation) and radiological emphysema in HIV-positive adults.\(^4\)

Interventions are required to address this health need. For populations with high levels of tobacco smoking, smoking cessation services should be prioritised. Earlier and more successful ART treatment may yield better lung health in the long term, although no significant differences in respiratory symptoms or lung function change were seen in HIV-positive adults with CD4 counts above 500 cells/\(\mu\)L randomised to early compared with deferred ART treatment in the recent START trial.\(^4\)

Furthermore, as highlighted in this review, there is little available evidence regarding the determinants of respiratory illness in HIV-positive individuals in resource-limited settings, where the majority of the world’s HIV-positive individuals live.

Acknowledgements We thank Ruth Muscat from the Royal Free Hospital library for assistance with database searches, and Monica Campo, Kristina Crothers, Jennifer Read and Jim Todd for providing their study data for analysis within this paper.

Contributors JB, AR, MJ, ML and IA planned the study, and JB is the guarantor of the work. JB, AR and SF undertook the literature review and selection of studies for inclusion in analysis. JB and AR undertook appraisal of the studies. JB and RH undertook statistical analysis. JB drafted the paper, and all authors revised and approved the final draft paper.

Funding JB is supported by an NIHR Doctoral Research Fellowship (DRF-2015-08-210).

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


Respiratory symptoms in people living with HIV and the effect of antiretroviral therapy: a systematic review and meta-analysis

James Brown, Anjana Roy, Ross Harris, Sarah Filson, Margaret Johnson, Ibrahim Abubakar and Marc Lipman

Thorax published online October 24, 2016

Updated information and services can be found at: http://thorax.bmj.com/content/early/2016/10/24/thoraxjnl-2016-208657

These include:

References
This article cites 46 articles, 7 of which you can access for free at: http://thorax.bmj.com/content/early/2016/10/24/thoraxjnl-2016-208657#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Open access (226)
Drugs: infectious diseases (968)
HIV/AIDS (194)
Internet (104)

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/